RGNX

In a report released today, Mani Foroohar from SVB Securities maintained a Hold rating on RegenXBio (RGNX - Research Report), with a price target of $14.00. The company's shares closed yesterday at $21.05.Foroohar covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Moderna, and Mirum Pharmaceuticals. According to TipRanks, Foroohar has an average return of -15.1% and a 40.39% success rate on recommended stocks. In addition to SVB Securities, RegenXBio also received a Hold from Wedbush's Andreas Argyrides in a report issued today. However, on the same day, Chardan Capital maintained a Buy rating on RegenXBio (NASDAQ: RGNX).
https://www.tipranks.com/news/blurbs/regenxbio-rgnx-gets-a-hold-from-svb-securities?utm_source=advfn.com&utm_medium=referral